Heron Therapeutics Inc vs United Airlines Holdings Inc — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while United Airlines Holdings Inc trades at $105.76 (market cap $34.87B). The key difference: United Airlines Holdings Inc is far larger — about 512.7× Heron Therapeutics Inc's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and United Airlines Holdings Inc for 46 Days on average.
| HRTX | UAL | |
|---|---|---|
Market Cap | $68.01M | $34.87B |
Volume | 1,891,941 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $1.49 | $136.11 |
52-Week Low | $0.27 | $85.21 |
Typical Hold Time | 35 Days | 46 Days |
Enterprise Value | $174.75M | $51.90B |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
United Airlines (UAL) trades at $110.17, down 1.53% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.06, net income margin of 5.56%, and three consecutive quarterly EPS beats. Recent news highlights aggressive customer acquisition tactics targeting Delta's elite travelers with status-match offers and Starlink WiFi advantages.
Outlook remains positive given analyst consensus of $158.10 price target and 66% buy ratings, but risks include rising fuel costs, labor expenses, and competitive pressures. Earnings growth and market share gains are key catalysts, though near-term volatility persists.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →